Hsbc Holdings PLC Acquires New Holdings in Altimmune, Inc. $ALT

Hsbc Holdings PLC acquired a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 72,258 shares of the company’s stock, valued at approximately $349,000. Hsbc Holdings PLC owned approximately 0.09% of Altimmune at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in ALT. Ameriprise Financial Inc. boosted its position in Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after purchasing an additional 1,378,854 shares in the last quarter. RFG Advisory LLC bought a new stake in Altimmune during the first quarter valued at about $1,622,000. Nuveen LLC purchased a new stake in Altimmune in the first quarter valued at about $1,304,000. Millennium Management LLC raised its stake in Altimmune by 139.8% in the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company’s stock valued at $2,492,000 after buying an additional 201,484 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Altimmune in the first quarter valued at about $939,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Down 1.9%

Shares of NASDAQ:ALT opened at $3.68 on Thursday. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $11.16. The stock has a market cap of $324.79 million, a price-to-earnings ratio of -3.12 and a beta of 0.18. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $3.91 and a 200-day moving average price of $5.01.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Equities analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of research analyst reports. The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research note on Thursday, July 10th. UBS Group decreased their price target on Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, August 13th. JMP Securities decreased their price target on Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a research note on Thursday, July 10th. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.40.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.